[go: up one dir, main page]

EP2971288A4 - COMPOSITIONS, METHODS, AND COMPUTER SYSTEMS ASSOCIATED WITH THE PRODUCTION AND ADMINISTRATION OF MODIFIED T CELLS - Google Patents

COMPOSITIONS, METHODS, AND COMPUTER SYSTEMS ASSOCIATED WITH THE PRODUCTION AND ADMINISTRATION OF MODIFIED T CELLS

Info

Publication number
EP2971288A4
EP2971288A4 EP14773595.5A EP14773595A EP2971288A4 EP 2971288 A4 EP2971288 A4 EP 2971288A4 EP 14773595 A EP14773595 A EP 14773595A EP 2971288 A4 EP2971288 A4 EP 2971288A4
Authority
EP
European Patent Office
Prior art keywords
administration
compositions
cells
modified
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP14773595.5A
Other languages
German (de)
French (fr)
Other versions
EP2971288A1 (en
Inventor
Roderick A Hyde
Wayne R Kindsvogel
Gary L Mcknight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elwha LLC
Original Assignee
Elwha LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/804,224 external-priority patent/US9587237B2/en
Priority claimed from US13/827,960 external-priority patent/US9499855B2/en
Priority claimed from US13/826,803 external-priority patent/US20140274801A1/en
Application filed by Elwha LLC filed Critical Elwha LLC
Publication of EP2971288A1 publication Critical patent/EP2971288A1/en
Publication of EP2971288A4 publication Critical patent/EP2971288A4/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP14773595.5A 2013-03-14 2014-03-11 COMPOSITIONS, METHODS, AND COMPUTER SYSTEMS ASSOCIATED WITH THE PRODUCTION AND ADMINISTRATION OF MODIFIED T CELLS Ceased EP2971288A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/804,224 US9587237B2 (en) 2013-03-14 2013-03-14 Compositions, methods, and computer systems related to making and administering modified T cells
US13/827,960 US9499855B2 (en) 2013-03-14 2013-03-14 Compositions, methods, and computer systems related to making and administering modified T cells
US13/826,803 US20140274801A1 (en) 2013-03-14 2013-03-14 Compositions, methods, and computer systems related to making and administering modified t cells
PCT/US2014/023650 WO2014159435A1 (en) 2013-03-14 2014-03-11 Compositions, methods, and computer systems related to making and administering modified t cells

Publications (2)

Publication Number Publication Date
EP2971288A1 EP2971288A1 (en) 2016-01-20
EP2971288A4 true EP2971288A4 (en) 2016-12-07

Family

ID=51625167

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14773595.5A Ceased EP2971288A4 (en) 2013-03-14 2014-03-11 COMPOSITIONS, METHODS, AND COMPUTER SYSTEMS ASSOCIATED WITH THE PRODUCTION AND ADMINISTRATION OF MODIFIED T CELLS

Country Status (2)

Country Link
EP (1) EP2971288A4 (en)
WO (1) WO2014159435A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3693384B1 (en) 2014-03-11 2024-01-24 Cellectis Method for generating t-cells compatible for allogenic transplantation
CN105985444B (en) * 2015-02-05 2024-02-13 博生吉安科细胞技术有限公司 Chimeric antigen receptor, and method and application for rapidly constructing chimeric antigen receptor
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
IL316764A (en) 2019-04-03 2025-01-01 Prec Biosciences Inc Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
WO2021062155A1 (en) * 2019-09-27 2021-04-01 The Regents Of The University Of California Dual-controlled drug and photoactivatable system for spatiotemporal control of cell therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1118661A1 (en) * 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
US20050026199A1 (en) * 2000-01-21 2005-02-03 Shaw Sandy C. Method for identifying biomarkers using Fractal Genomics Modeling
CA2440474A1 (en) * 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment
AT503861B1 (en) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING T-CELL RECEPTORS
SG10201502661SA (en) * 2006-10-11 2015-05-28 Antitope Ltd T cell epitope databases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAMERON J TURTLE ET AL: "Engineered T cells for anti-cancer therapy", CURRENT OPINION IN IMMUNOLOGY., vol. 24, no. 5, 18 July 2012 (2012-07-18), GB, pages 633 - 639, XP055272888, ISSN: 0952-7915, DOI: 10.1016/j.coi.2012.06.004 *
CHRISTOPHER C KLOSS ET AL: "Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells", NATURE BIOTECHNOLOGY, vol. 31, no. 1, 16 December 2012 (2012-12-16), pages 71 - 75, XP055130697, ISSN: 1087-0156, DOI: 10.1038/nbt.2459 *
KEN-ICHI HANADA ET AL: "nature biotechnology volume 31 number 1 JAnuArY 2013 33", 1 January 2013 (2013-01-01), XP055290041, Retrieved from the Internet <URL:http://www.nature.com/nbt/journal/v31/n1/pdf/nbt.2471.pdf> [retrieved on 20160720] *
SCOTT WILKIE ET AL: "Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling", JOURNAL OF CLINICAL IMMUNOLOGY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 32, no. 5, 17 April 2012 (2012-04-17), pages 1059 - 1070, XP035113362, ISSN: 1573-2592, DOI: 10.1007/S10875-012-9689-9 *
See also references of WO2014159435A1 *
UTTENTHAL BENJAMIN J ET AL: "Challenges in T cell receptor gene therapy.", THE JOURNAL OF GENE MEDICINE JUN 2012, vol. 14, no. 6, June 2012 (2012-06-01), pages 386 - 399, XP002760096, ISSN: 1521-2254 *

Also Published As

Publication number Publication date
WO2014159435A1 (en) 2014-10-02
EP2971288A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
EP3529780A4 (en) SYSTEMS AND METHODS FOR DISPLAYING REPRESENTATIVE IMAGES
EP2997531A4 (en) METHODS AND SYSTEMS FOR PROVIDING PAYMENT IDENTIFIERS
EP2956754A4 (en) SYSTEMS AND METHODS OF MULTIPLE ANALYSIS
EP2968847A4 (en) TRANSLATION CATHETERS, SYSTEMS AND METHODS OF USE
EP2547329A4 (en) THERMOSTICALLY ADVERTISING SYSTEMS WITH MODIFIED SURFACES
EP2806781A4 (en) IMAGING SYSTEMS AND METHODS
EP2970872A4 (en) MICROORGANISMS AND METHODS FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES BASED ON N-ACETYLGLUCOSAMINE
EP2856524A4 (en) ELECTROLUMINESCENT ELEMENT HOUSINGS, ELECTROLUMINESCENT ELEMENT SYSTEMS, AND METHODS
EP2964768A4 (en) CELL EXPRESSION SYSTEM
EP2919659A4 (en) MULTI-MODAL IMAGING SYSTEMS, PROBES AND ASSOCIATED METHODS
EP2973789A4 (en) PROTECTED ELECTRODE STRUCTURES AND METHODS
EP2986623A4 (en) C3,3-DISUBSTITUTED 19-NOR-C21-N-PYRAZOLYL-STEROIDS AND METHODS OF USE THEREOF
EP2972921A4 (en) MOBILE COMPUTING TECHNOLOGY, AND SYSTEMS AND METHODS USING THE SAME
EP2948407A4 (en) HYDROGEN PRODUCTION SYSTEM AND METHODS OF USING THE SAME
EP2734905A4 (en) INTERFACE, SYSTEMS AND METHODS OF AVIONIC GUNWAY
EP2948375A4 (en) AIRCRAFT PUSH, ASSEMBLY AND METHODS
EP2828937A4 (en) CONNECTORS WITH ELECTRICITY OR SIGNAL CAPABILITY AND ASSOCIATED METHODS
EP2946345A4 (en) METHODS AND SYSTEMS OF GENETIC ANALYSIS
EP2665639A4 (en) AUTOMATIC LOCKING ATTACH SYSTEMS AND ASSOCIATED METHODS
EP2906281A4 (en) DOUBLE OXYGEN CONCENTRATOR SYSTEMS AND ASSOCIATED METHODS
EP2951313A4 (en) BIOMARKERS ASSOCIATED WITH PROGRESSION OF INSULIN RESISTANCE AND METHODS OF USE THEREOF
EP3368502A4 (en) ELECTROCHEMICAL, HALOGENATION, AND OXYHALOGENATION SYSTEMS AND METHODS
EP3015721A4 (en) JOINT, AND AIRCRAFT STRUCTURE
EP2697607A4 (en) ACCELEROMETER SYSTEMS AND METHODS
EP2925260A4 (en) SYSTEMS AND METHODS FOR INTRAOCULAR LENS INTRODUCTION

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151014

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G06F 19/00 20110101ALI20160722BHEP

Ipc: C40B 40/02 20060101AFI20160722BHEP

Ipc: C12N 5/0783 20100101ALI20160722BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20161108

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0783 20100101ALI20161102BHEP

Ipc: C40B 40/02 20060101AFI20161102BHEP

Ipc: G06F 19/00 20110101ALI20161102BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170928

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20190606